Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

100186

	registered interest
	date	21/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Patients: Safety
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, whether missed or inadequate hydrocortisone administration is included in the NHS list of Never Events.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	211233
	answer	answer is ministerial correction date of answer 28/10/2014 answer text <p>Missed or inadequate hydrocortisone administration is not currently included in the list of ‘never events’.</p><p> </p><p> </p><p> </p><p>We can confirm that the current list of Never Events is under review and there is a consultation underway which opened online on the 6 October 2014 and closes on 31 October 2014.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 28/10/2014 15:28:25 question first ministerially corrected 28/10/2014 16:30:53 answering member 4020 label Biography information for George Freeman previous answer version 24770 answering member constituency Battersea answering member printed Jane Ellison answering member 3918 label Biography information for Jane Ellison
	tabling member	95 label Biography information for Mr Andrew Smith

156585

	registered interest
	date	19/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Influenza: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will make it his policy to impose a statutory obligation on the employers of home care workers to provide free influenza vaccinations to their home care employees.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	215142
	answer	answer is ministerial correction date of answer 26/11/2014 answer text <p>We have no plans to mandate the provision of the annual flu vaccination.</p><p> </p><p> </p><p> </p><p>Frontline health and social care workers have a duty of care to protect their patients and service users, colleagues and family members from infection. Therefore, as in previous years, free flu immunisation should be offered by National Health Service organisations to all employees directly involved in delivering care. This is not an NHS service, but an occupational health responsibility being provided to NHS staff by employers. Social care providers and independent primary care providers should also consider vaccination of staff.</p><p> </p><p> </p><p> </p><p>The Health and Social Care Act 2008, Code of Practice on the prevention and control of infections and related guidance, emphasises the need to ensure, so far as is reasonably practicable, that care workers are free of and are protected from exposure to infections that can be caught at work and that all staff are suitably educated in the prevention and control of infection associated with the provision of health and social care.</p><p> </p><p> </p><p> </p><p>The Code of Practice states that registered providers should ensure that policies and procedures are in place in relation to the prevention and control of infection. This includes access to occupational health services and that employers should make vaccine available free of charge to employees if a risk assessment indicates that it is needed.</p><p> </p><p> </p><p> </p><p>A copy of the Health and Social Care Act 2008, Code of Practice is attached.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 215143 question first answered 26/11/2014 17:37:46 answering member 3918 label Biography information for Jane Ellison attachment 1 file name The Health and Social Care Act 2008- Code of Practice.pdf title Code of Practice
	tabling member	95 label Biography information for Mr Andrew Smith

156586

	registered interest
	date	19/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Influenza: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will require it to be a condition of commissioning home care provision that employers of home care workers pay for influenza vaccinations for their domiciliary workforce.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	215143
	answer	answer is ministerial correction date of answer 26/11/2014 answer text <p>We have no plans to mandate the provision of the annual flu vaccination.</p><p> </p><p> </p><p> </p><p>Frontline health and social care workers have a duty of care to protect their patients and service users, colleagues and family members from infection. Therefore, as in previous years, free flu immunisation should be offered by National Health Service organisations to all employees directly involved in delivering care. This is not an NHS service, but an occupational health responsibility being provided to NHS staff by employers. Social care providers and independent primary care providers should also consider vaccination of staff.</p><p> </p><p> </p><p> </p><p>The Health and Social Care Act 2008, Code of Practice on the prevention and control of infections and related guidance, emphasises the need to ensure, so far as is reasonably practicable, that care workers are free of and are protected from exposure to infections that can be caught at work and that all staff are suitably educated in the prevention and control of infection associated with the provision of health and social care.</p><p> </p><p> </p><p> </p><p>The Code of Practice states that registered providers should ensure that policies and procedures are in place in relation to the prevention and control of infection. This includes access to occupational health services and that employers should make vaccine available free of charge to employees if a risk assessment indicates that it is needed.</p><p> </p><p> </p><p> </p><p>A copy of the Health and Social Care Act 2008, Code of Practice is attached.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 215142 question first answered 26/11/2014 17:37:46 answering member 3918 label Biography information for Jane Ellison attachment 1 file name The Health and Social Care Act 2008- Code of Practice.pdf title Code of Practice
	tabling member	95 label Biography information for Mr Andrew Smith

166003

	registered interest
	date	25/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Social Services: Pay
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, if he will include in the Social Care Commitment, a statement about employer compliance with minimum wage legislation.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	215814
	answer	answer is ministerial correction date of answer 02/12/2014 answer text <p>To make the Social Care Commitment, employers must first commit to ensuring good employment practice. Employers are therefore agreeing to offer fair terms and conditions to all of their employees and to take active steps to ensure that their employment practice complies with employment legislation, including paying the National Minimum Wage as a minimum, and provides additional benefits or enhanced terms and conditions where possible. This is included under the terms and conditions of acceptance of the Social Care Commitment.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 02/12/2014 16:04:13 answering member 1439 label Biography information for Norman Lamb
	tabling member	95 label Biography information for Mr Andrew Smith

171817

	registered interest
	date	02/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what response he has made to the request by NHS England to defer implementation of the guidance on sofosbuvir for hepatitis C.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	219601
	answer	answer is ministerial correction date of answer 09/01/2015 answer text <p>As an independent body, it is for the National Institute for Health and Care Excellence (NICE), in consultation with stakeholders, to consider NHS England’s request to defer implementation of its guidance on sofosbuvir (Sovaldi) for the treatment of chronic hepatitis C.</p><p> </p><p> </p><p> </p><p>NICE recently consulted on extending the funding period and we understand that NICE expects to publish the outcome of that consultation, along with its final draft guidance on sofosbuvir, later this month. The Department’s response to the consultation will be published alongside other stakeholders’ comments. We are confident that NICE will carefully consider all the comments it has received before taking a final decision.</p><p> </p><p> </p><p> </p><p>NICE currently expects to publish its final guidance on sofosbuvir in February 2015, although this is subject to any appeals being received.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 219602 question first answered 09/01/2015 14:33:04 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

171818

	registered interest
	date	02/01/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when NICE guidance on the use of sofosbuvir for treating hepatitis C will be published.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	219602
	answer	answer is ministerial correction date of answer 09/01/2015 answer text <p>As an independent body, it is for the National Institute for Health and Care Excellence (NICE), in consultation with stakeholders, to consider NHS England’s request to defer implementation of its guidance on sofosbuvir (Sovaldi) for the treatment of chronic hepatitis C.</p><p> </p><p> </p><p> </p><p>NICE recently consulted on extending the funding period and we understand that NICE expects to publish the outcome of that consultation, along with its final draft guidance on sofosbuvir, later this month. The Department’s response to the consultation will be published alongside other stakeholders’ comments. We are confident that NICE will carefully consider all the comments it has received before taking a final decision.</p><p> </p><p> </p><p> </p><p>NICE currently expects to publish its final guidance on sofosbuvir in February 2015, although this is subject to any appeals being received.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 219601 question first answered 09/01/2015 14:33:04 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

178985

	registered interest
	date	10/02/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, with reference to his Department's report, Hepatitis C in the UK, published in July 2014, what steps he is taking to approve for use new treatments for people with hepatitis C-related liver damage.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	223984
	answer	answer is ministerial correction date of answer 23/02/2015 answer text <p>The Government is committed to ensuring that patients have access to clinically and cost effective treatments, including those for hepatitis C.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the National Health Service on the clinical and cost-effectiveness of health technologies.</p><p> </p><p> </p><p> </p><p>NICE is currently appraising a number of new drugs for use in the treatment of hepatitis C under its technology appraisal process. These are shown in the following table.</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Drug/indication</p></td><td><p>Expected date of final guidance</p></td></tr><tr><td><p>sofosbuvir (Sovaldi) for treating chronic hepatitis C</p></td><td><p>February 2015</p></td></tr><tr><td><p>simeprevir (Olysio) for treating genotype 1 or 4 chronic hepatitis C</p></td><td><p>February 2015</p></td></tr><tr><td><p>ledipasvir-sofosbuvir (Harvoni) for treating chronic hepatitis C</p></td><td><p>June 2015</p></td></tr><tr><td><p>daclatasvir (Daklinza) for treating chronic hepatitis C</p></td><td><p>August 2015</p></td></tr><tr><td><p>ombitasvir/paritaprevir/ritonavir (Viekirax) with or without dasabuvir (Exviera) for treating chronic hepatitis C</p></td><td><p>September 2015</p></td></tr></tbody></table><p> </p><p><strong> </strong></p><p> </p><p>More generally, we have launched an Innovative Medicines and Medical Technology Review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p> </p><p> </p><p>The review will examine the pathway from ‘first in human’ trials, through licensing and health technology appraisal, to commissioning and clinical practice. It will set out both short and long-term options for action by Government and relevant bodies, including NICE, the Medicines and Healthcare products Regulatory Agency and NHS England, and mark a major contribution to the policy debate.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 23/02/2015 16:20:22 answering member 4020 label Biography information for George Freeman
	tabling member	95 label Biography information for Mr Andrew Smith

222574

	registered interest
	date	20/02/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Crohn's Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what support his Department is providing to research into the treatment of Crohn's disease.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	224718
	answer	answer is ministerial correction date of answer 26/02/2015 answer text <p>The Department’s National Institute for Health Research (NIHR) funds a range of research relating to treatment of Crohn’s disease.</p><p> </p><p> </p><p> </p><p>The NIHR has awarded nearly £1.5 million over five years to August 2018 for a research professorship at the University of Oxford. This is focussed on re-defining Crohn’s disease at a molecular level to identify new biomarkers and therapies.</p><p> </p><p> </p><p> </p><p>The NIHR Health Technology Assessment programme is seeking to commission a systematic review looking at whether patients can be identified who may need early intensive treatment in Crohn’s disease.</p><p> </p><p> </p><p> </p><p>The NIHR Clinical Research Network is currently recruiting patients to six studies relating to treatment of Crohn’s disease.</p><p> </p><p><strong> </strong></p><p> </p><p>The NIHR welcomes funding applications for research into any aspect of human health, including Crohn’s disease. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 26/02/2015 15:13:29 answering member 3918 label Biography information for Jane Ellison
	tabling member	95 label Biography information for Mr Andrew Smith

222575

	registered interest
	date	20/02/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Crohn's Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what his policy is on the provision of counselling and support to those with Crohn's disease.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	224719
	answer	answer is ministerial correction date of answer 25/02/2015 answer text <p>The Department has made no assessment of the incidence of Crohn’s disease. However, the National Institute for Health and Care Excellence (NICE) 2012 guideline <em>Crohn’s Disease Management in Adults, Children and Young People</em>, states that there are currently at least 115,000 people in the United Kingdom with Crohn's disease.</p><p> </p><p> </p><p> </p><p>The NICE guideline sets out best practice on the diagnosis, treatment, care and support of people with Crohn’s disease. This includes, ‘<em>M</em><em>inimising psychological concerns and possible side effects of treatment are fundamental to best practice for all people with Crohn's disease, whatever their age</em>’, which could include access to psychological support, if appropriate. The guideline also recommends that clinicians give patients with Crohn’s disease contact details for relevant support groups. The full guideline can be found at the following link: www.nice.org.uk/guidance/cg152.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 224776 question first answered 25/02/2015 15:12:44 answering member 1439 label Biography information for Norman Lamb
	tabling member	95 label Biography information for Mr Andrew Smith

222594

	registered interest
	date	20/02/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Crohn's Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what assessment his Department has made of trends in the incidence of Crohn's disease.
	tabling member constituency	Oxford East
	tabling member printed	Mr Andrew Smith
	uin	224776
	answer	answer is ministerial correction date of answer 25/02/2015 answer text <p>The Department has made no assessment of the incidence of Crohn’s disease. However, the National Institute for Health and Care Excellence (NICE) 2012 guideline <em>Crohn’s Disease Management in Adults, Children and Young People</em>, states that there are currently at least 115,000 people in the United Kingdom with Crohn's disease.</p><p> </p><p> </p><p> </p><p>The NICE guideline sets out best practice on the diagnosis, treatment, care and support of people with Crohn’s disease. This includes, ‘<em>M</em><em>inimising psychological concerns and possible side effects of treatment are fundamental to best practice for all people with Crohn's disease, whatever their age</em>’, which could include access to psychological support, if appropriate. The guideline also recommends that clinicians give patients with Crohn’s disease contact details for relevant support groups. The full guideline can be found at the following link: www.nice.org.uk/guidance/cg152.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 224719 question first answered 25/02/2015 15:12:44 answering member 1439 label Biography information for Norman Lamb
	tabling member	95 label Biography information for Mr Andrew Smith